SCHEMBL7181292

SCHEMBL7181292

COc1cc(OC)c(C(=O)[P](=O)c2ccccc2C(=O)c2c(C)c(C)c(C)c(C)c2C)c(OC)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.38
KMT2A Q03164 4/20 0.38
CYP3A4 P08684 3/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
MAPT P10636 2/20 0.38
USP2 O75604 1/20 0.38
MAPK1 P28482 1/20 0.38
TP53 P04637 1/20 0.38
ATM Q13315 1/20 0.38
HSD17B10 Q99714 1/20 0.38
ABCG2 Q9UNQ0 3/20 0.37
MAOA P21397 1/20 0.37
MAOB P27338 1/20 0.37
NPC1 O15118 2/20 0.36
MEN1 O00255 1/20 0.36
RAB9A P51151 1/20 0.36
HPGD P15428 2/20 0.35
LMNA P02545 1/20 0.35
CYP1A2 P05177 1/20 0.35
PGR P06401 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7733699 0.93 ALDH1A1 (0.39) ALDH1A1KMT2ACYP3A4SMN1; SMN2MAPT
SCHEMBL7185356 0.91 ALDH1A1 (0.38) ALDH1A1KMT2ACYP3A4SMN1; SMN2MAPT
SCHEMBL7183272 0.90 CA12 (0.41) KMT2ATP53NPC1RAB9A
SCHEMBL7189932 0.89 ALDH1A1 (0.39) ALDH1A1KMT2ACYP3A4SMN1; SMN2MAPT
SCHEMBL7736110 0.89 ALDH1A1 (0.43) ALDH1A1KMT2ACYP3A4SMN1; SMN2MAPT
SCHEMBL7188977 0.89 MAPT (0.41) ALDH1A1KMT2ACYP3A4SMN1; SMN2MAPT
SCHEMBL7187667 0.88 ALDH1A1 (0.38) ALDH1A1KMT2ACYP3A4SMN1; SMN2MAPT
SCHEMBL7178052 0.88 ABCB1 (0.40) ALDH1A1KMT2ACYP3A4SMN1; SMN2MAPT
SCHEMBL7182505 0.86 KMT2A (0.40) ALDH1A1KMT2ACYP3A4SMN1; SMN2MAPT
SCHEMBL7180294 0.86 ALDH1A1 (0.43) ALDH1A1KMT2ACYP3A4SMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 ALDH1A1 3984/4885KMT2A 956/4885CYP3A4 1881/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.